Flemming Ørnskov takes on a new challenge, driving a $10B dermatology spinout with some big plans for growth
Just as Galderma was being spun out of Nestlé with plans to become the biggest independent dermatology company on the planet, they signed a new, high profile CEO and CFO who have built their reputations around driving growth at Shire, setting the stage for a $62 billion Takeda buyout.
Flemming Ornskov and Thomas Dittrich, who shook up Shire — hard — to make it into a top player in rare diseases and ophthalmology, took the two top spots at Galderma, which officially rebranded from Nestlé Skin Health a week ago following a 10.2 billion CHF deal.
Stuart Raetzman, Nestlé Skin Health’s CEO for the past 3 years, switched to a director’s role.
Ornskov had this to say about his new post:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.